Annual CFF:
$659.51M+$650.60M(+7300.21%)Summary
- As of today, NAMS annual cash from financing is $659.51 million, with the most recent change of +$650.60 million (+7300.21%) on December 31, 2024.
- During the last 3 years, NAMS annual cash from financing has risen by +$574.80 million (+678.60%).
- NAMS annual cash from financing is now at all-time high.
Performance
NAMS Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly CFF:
$5.89M+$2.47M(+72.03%)Summary
- As of today, NAMS quarterly cash from financing is $5.89 million, with the most recent change of +$2.47 million (+72.03%) on September 30, 2025.
- Over the past year, NAMS quarterly cash from financing has increased by +$5.83 million (+10058.62%).
- NAMS quarterly cash from financing is now -98.71% below its all-time high of $456.61 million, reached on December 31, 2024.
Performance
NAMS Quarterly Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
$472.45M+$5.83M(+1.25%)Summary
- As of today, NAMS TTM cash from financing is $472.45 million, with the most recent change of +$5.83 million (+1.25%) on September 30, 2025.
- Over the past year, NAMS TTM cash from financing has increased by +$269.55 million (+132.85%).
- NAMS TTM cash from financing is now -28.36% below its all-time high of $659.51 million, reached on December 31, 2024.
Performance
NAMS TTM Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
NAMS Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +7300.2% | +10000.0% | +132.8% |
| 3Y3 Years | +678.6% | +100.0% | +10000.0% |
| 5Y5 Years | +4636.8% | - | - |
NAMS Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +7300.2% | -98.7% | >+9999.0% | -28.4% | >+9999.0% |
| 5Y | 5-Year | at high | +7300.2% | -98.7% | >+9999.0% | -28.4% | >+9999.0% |
| All-Time | All-Time | at high | +7300.2% | -98.7% | >+9999.0% | -28.4% | >+9999.0% |
NAMS Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2025 | - | $5.89M(+72.0%) | $472.45M(+1.3%) |
| Jun 2025 | - | $3.42M(-47.5%) | $466.61M(-0.3%) |
| Mar 2025 | - | $6.52M(-98.6%) | $467.85M(-29.1%) |
| Dec 2024 | $659.51M(+7300.2%) | $456.61M(>+9900.0%) | $659.51M(+225.0%) |
| Sep 2024 | - | $58.00K(-98.8%) | $202.90M(+0.0%) |
| Jun 2024 | - | $4.66M(-97.6%) | $202.84M(+2.4%) |
| Mar 2024 | - | $198.18M(+8185.1%) | $198.18M(+8185.1%) |
| Dec 2023 | $8.91M(-97.7%) | - | - |
| Mar 2023 | - | $2.39M | $2.39M |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2022 | $391.90M(+362.7%) | - | - |
| Sep 2022 | - | $0.00(0.0%) | -$45.00K(0.0%) |
| Jun 2022 | - | $0.00(+100.0%) | -$45.00K(0.0%) |
| Mar 2022 | - | -$45.00K(>-9900.0%) | -$45.00K(>-9900.0%) |
| Dec 2021 | $84.70M(+508.4%) | $0.00(0.0%) | $0.00(0.0%) |
| Sep 2021 | - | $0.00(0.0%) | $0.00(0.0%) |
| Jun 2021 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2021 | - | $0.00 | $0.00 |
| Dec 2020 | $13.92M | - | - |
FAQ
- What is NewAmsterdam Pharma Company N.V. annual cash from financing?
- What is the all-time high annual cash from financing for NewAmsterdam Pharma Company N.V.?
- What is NewAmsterdam Pharma Company N.V. annual cash from financing year-on-year change?
- What is NewAmsterdam Pharma Company N.V. quarterly cash from financing?
- What is the all-time high quarterly cash from financing for NewAmsterdam Pharma Company N.V.?
- What is NewAmsterdam Pharma Company N.V. quarterly cash from financing year-on-year change?
- What is NewAmsterdam Pharma Company N.V. TTM cash from financing?
- What is the all-time high TTM cash from financing for NewAmsterdam Pharma Company N.V.?
- What is NewAmsterdam Pharma Company N.V. TTM cash from financing year-on-year change?
What is NewAmsterdam Pharma Company N.V. annual cash from financing?
The current annual cash from financing of NAMS is $659.51M
What is the all-time high annual cash from financing for NewAmsterdam Pharma Company N.V.?
NewAmsterdam Pharma Company N.V. all-time high annual cash from financing is $659.51M
What is NewAmsterdam Pharma Company N.V. annual cash from financing year-on-year change?
Over the past year, NAMS annual cash from financing has changed by +$650.60M (+7300.21%)
What is NewAmsterdam Pharma Company N.V. quarterly cash from financing?
The current quarterly cash from financing of NAMS is $5.89M
What is the all-time high quarterly cash from financing for NewAmsterdam Pharma Company N.V.?
NewAmsterdam Pharma Company N.V. all-time high quarterly cash from financing is $456.61M
What is NewAmsterdam Pharma Company N.V. quarterly cash from financing year-on-year change?
Over the past year, NAMS quarterly cash from financing has changed by +$5.83M (+10058.62%)
What is NewAmsterdam Pharma Company N.V. TTM cash from financing?
The current TTM cash from financing of NAMS is $472.45M
What is the all-time high TTM cash from financing for NewAmsterdam Pharma Company N.V.?
NewAmsterdam Pharma Company N.V. all-time high TTM cash from financing is $659.51M
What is NewAmsterdam Pharma Company N.V. TTM cash from financing year-on-year change?
Over the past year, NAMS TTM cash from financing has changed by +$269.55M (+132.85%)